Sandoz’s Jubbonti (biosimilar, denosumab) Receives Health Canada’s Approval for the Treatment of Osteoporosis
Shots:
- Health Canada has approved the Jubbonti subcutaneous injection to treat osteoporosis and increase bone mass. The approval is based on the results of Phase I and Phase III clinical studies results that show Jubbonti has the same safety and risk as the reference medicine (Prolia)
- This human mAb and ligand inhibitor (bone metabolism regulator) is also approved to treat all five indications, just like the reference medicine
- Sandoz continued the expansion of Jubbonti and will be available in the Canadian market in the coming month as a 60 mg/mL solution in a single-use prefilled syringe
Ref: sandoz | Image: sandoz
Related News:- Sandoz Introduces High-Concentration Formulation of Hyrimoz in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
